CN103751838A - Preparation method of VEGF (Vascular Endothelial Growth Factor)-loaded porous hydroxyapatite bracket - Google Patents
Preparation method of VEGF (Vascular Endothelial Growth Factor)-loaded porous hydroxyapatite bracket Download PDFInfo
- Publication number
- CN103751838A CN103751838A CN201410005889.2A CN201410005889A CN103751838A CN 103751838 A CN103751838 A CN 103751838A CN 201410005889 A CN201410005889 A CN 201410005889A CN 103751838 A CN103751838 A CN 103751838A
- Authority
- CN
- China
- Prior art keywords
- vegf
- porous
- hydroxyapatite
- plga
- support
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Abstract
The invention discloses a preparation method of a VEGF (Vascular Endothelial Growth Factor)-loaded porous hydroxyapatite bracket. The preparation method comprises the following steps of adding PLGA (Poly(Lactic-co-Glycolic Acid) microspheres to a die; transferring in an oven for a while until the PLGA microspheres are slightly adhered, so as to obtain a porous PLGA bracket; soaking the PLGA bracket into a diammonium hydrogen phosphate solution; dropping a calcium nitrate solution; regulating pH (Power of Hydrogen) with ammonia water; ageing a reactant; washing a product with distilled water; drying; roasting to remove PLGA to obtain a porous connected hydroxyapatite; soaking the hydroxyapatite bracket into a VEGF solution; transferring into a vacuum dryer; and then freezing and drying to obtain the VEGF loaded porous hydroxyapatite bracket. The prepared VEGF loaded bracket is high in porosity, has pore connection rate closing to 100%, and is also high in biocompatibility, high in VEGF loading rate, and controllable on medicine release rate; the preparation process is simple, the raw materials are easily available, the cost is low, and industrialization is easily realized.
Description
Technical field
The invention belongs to the preparing technical field of biomedical material, relate to the technology of preparing of medicine carrying Injectable microspheres, be specifically related to the preparation method of a kind of year VEGF porous hydroxyapatite support.
Background technology
In recent years, the damaged patient's quantity of China's bone is ascendant trend year by year.Disclose the mechanism of bone defect repair, the method for finding the damaged good reparation of bone is that bone defect repair research field is badly in need of the key issue solving.The method of traditional repairing bone defects such as early stage autologous bone transplanting, allogenic bone transplantation is large and poor effect to body injury; Artificial bone substitute is because biocompatibility is poor, vivo degradation is slow and mechanical performance is low etc. former thereby extensively do not promote afterwards; The reparation that appears as jaw defect of bone tissue engineer bone in recent years brings new hope.Bone tissue engineer technology has changed the pattern of traumatic reparation in the past, with a small amount of histiocyte, repair large area tissue defect, and can carry out as required the damaged form of moulding recovery, for realizing noinvasive reparation and good biological function, rebuild that theoretical basis is provided is that osteanagenesis reparation has indicated new direction.Some larger area bones are damaged because implant is often because lacking sufficient blood for necrosing.Therefore, the key factor of bone tissue engineer has been listed in effective vascularization in.It is to make the most direct effective method of bone substitute vascularization that preformation blood vessel is implanted, but is confined to the reparation of the damaged and soft-tissue trauma of small size bone because the deficiencies such as experience Repeated Operation, damage blood supply area under control and treatment cycle are long make the method; The factor that induction of vascular generates is as VEGF (Vascular Endothelial Growth Factor, VEGF), fibroblast growth factor (Fibroblast growth factor, FGF), angiotensin (Angiopoietin, Ang) use can promote angiogenesis, but because of the direct effect in short part of half-life not good enough.Therefore, the carrier that we adopt porous support that current research is one of the most extensive to discharge as VEGF, to solve short problem of VEGF half-life.
Apatite is the synthos mineral that occurring in nature extensively exists, it is the main inorganic composition of sclerous tissues in mammalian body, very approaching with natural apatite mineral structure, in people's bone, account for 77%, in dentary up to 97%, it is the main inorganic composition of vertebrates bone and tooth, there is good biocompatibility, and the hydroxyapatite with loose structure is except having the excellent properties of general pottery, more be conducive to growing into of biological tissue's organ, its hole being interconnected is conducive to the microcirculation of tissue fluid, can provide nutrition for the area of new bone in hydroxyapatite deep, promote combination and the growth of fibrous tissue and area of new bone, it is the hard tissue substituting material that a kind of performance is better.From the angle of implanting, the physical chemistry composition of hydroxyapatite and the inorganic composition of human bone are closely similar, and crystal structure is also similar, after porous hydroxyapatite implant into body, nature bone is invaded and is merged gradually with it from the hole of porous hydroxyapatite, make intensity and the toughness of the hydroxyapatite implanted more and more close with natural bone, make it have good mechanical performance.In preparing the process of Porous Hydroxyapatite Ceramic, by the control to its preparation technology, and be written into the somatomedin such as certain density VEGF, obtain the Many Stomas Hydroxyapatlte Biomaterial of high bioactivity, prepare suitable biodegradable porous hydroxyapatite carrier, the somatomedin such as VEGF are written into rear arrival bone defect and delay controlled release and put, make the concentration of its release maintain the regular hour, the Yu Heneng of defective tissue is played an important role.The method of preparing at present porous hydroxyapatite has 1) chemical blowing process, while preparing porous hydroxyapatite in this way for aperture and the more difficult control of voidage of porous material, and the hole major part of the porous material that this method obtains is sealed, the perforation rate of pore is poor; 2) pore creating material method, but prepared porous hydroxyapatite porosity is not high, and pore diameter range wider distribution; 3) foam impregnation method, but in the process of dry and sintering, very easily on biomaterial, produce fine crack, reduced the intensity of porous hydroxyapatite; 4) organic formwork method, but this method need to be selected suitable surfactant, and selected surfactant may be poisonous in some cases, needs at high temperature just can remove, and so just reduced the biological activity of porous hydroxyapatite.
The present invention chooses microsphere support that pore communication is very excellent as template, then porous hydroxyapatite support is soaked in VEGF solution, obtains carrying the porous hydroxyapatite support of VEGF; This technique does not need surfactant, and template can be directly removed in calcining; By the particle diameter of regulation and control microsphere, can make the porous hydroxyapatite support of different pore size, and then VEGF load factor and the Release Performance of regulation and control porous support, almost 100% UNICOM of a kind of hole, effectively release, the porous support of Angiogensis and good biocompatibility.
Chinese patent 98811634.0 discloses the porous hydroxyapatite particles as pharmaceutical carrier; Chinese patent 201110101899.2 discloses a kind of porous hydroxyapatite and preparation method thereof and application; Chinese patent 201210058017.3 discloses a kind of porous hydroxyapatite bioceramic and preparation method thereof; Chinese patent 201310051813.9 discloses flower-shaped microsphere of a kind of porous hydroxyapatite and preparation method thereof; Shi Jianjun etc. [build up the Army, Song Zaiyi, Qi Zhiping by time.Microemulsion method is prepared gentamycin porous hydroxyapatite microsphere, Journal of Chinese Hospital Pharmacy, 2013.14.1-5] the gentamycin porous hydroxyapatite microsphere that carries of preparation is studied; [Zhao Kang, Wei Junqi, Luo Defu, Tang Yufei, the Xu Lei such as Zhao Kang.Freeze-drying is prepared hydroxyapatite porous support, silicate journal, 2009.3.432-435] prepared hydroxyapatite porous support.But the porous hydroxyapatite ubiquity hole UNICOM that above-mentioned prior art makes is bad, the problem that medicine loading performance is poor.
Summary of the invention
The object of the invention is to the shortcoming for prior art, the preparation method of a kind of year VEGF porous hydroxyapatite support is provided.First the present invention prepares PLGA porous support, and then support is soaked in ammonium dibasic phosphate solution, drip calcium nitrate solution, after calcining, obtain the hydroxyapatite scaffold of porous UNICOM, again this support is soaked in VEGF solution, obtains carrying VEGF porous hydroxyapatite support.In preparation of the present invention (1) by hydroxyapatite deposition on the PLGA of porous UNICOM microsphere support, by regulating and controlling the particle diameter of this PLGA microsphere, the aperture of the hydroxyapatite scaffold can Effective Regulation making; (2) pore communication of the template PLGA microsphere support of selecting is very excellent, and the hydroxyapatite scaffold connectivity making is good, moderate strength; (3) hydroxyapatite scaffold making, owing to removing the cellular loose structure of class staying after microsphere, can effectively promote medicine, the absorption of albumen; (4) timbering material is hydroxyapatite, is the main inorganic composition of biological skeleton, has good biocompatibility with sclerous tissues, has good affinity and bone conductibility with sclerous tissues; (5) preparation method technique is simple, and equipment is not had to excessive demand, and raw material is easy to get, with low cost, is easy to realize industrialization.
In order to achieve the above object, the present invention has adopted following technical scheme.
The preparation method of carrying VEGF porous hydroxyapatite support, comprises the following steps:
(1) the PLGA microsphere of 25～200 μ m is poured in mould, in baking oven, 50～70 ℃ of placement 10～30min make it to bond a little, obtain porous PLGA support;
(2) porous PLGA support is soaked in to 0.08～0.16molL
-1100～200mL ammonium dibasic phosphate aqueous solution in, with the speed of 1～3 drop/sec, drip 0.18～0.36molL
-1100～200mL calcium nitrate aqueous solution, then use ammonia adjust pH to 9～12, reactant is in 65～90 ℃ of ageings after 4～6 days, use distilled water wash product, in 30～50 ℃ of oven dry, then remove PLGA in 400～800 ℃ of calcinings, obtain the hydroxyapatite scaffold of porous UNICOM;
(3) hydroxyapatite scaffold of porous UNICOM is soaked in the VEGF solution of 50～150 μ g/mL, is placed in vacuum desiccator and keeps 30～90min, then lyophilization, obtains carrying the porous hydroxyapatite support of VEGF, in 4 ℃ of sealings, saves backup.
In said method, described in step (2), the mass volume ratio of PLGA support and ammonium dibasic phosphate solution is (1～4): 100g/mL.
In said method, in step (2), the calcium phosphorus atoms ratio of described calcium nitrate solution and ammonium dibasic phosphate solution is (1.66～1.68): 1.
In said method, described in step (2), calcination time is 3～6h.
In said method, described in step (2), with distilled water wash product number of times, it is 3～5 times.
In said method, in step (3), described sublimation drying is 40～60h.
The present invention compared with prior art, has the following advantages and beneficial effect:
(1) by hydroxyapatite deposition on the PLGA of porous UNICOM microsphere support, by regulating and controlling the particle diameter of this PLGA microsphere, the aperture of the hydroxyapatite scaffold can Effective Regulation making.
(2) pore communication of the template PLGA microsphere support of selecting is very excellent, and the hydroxyapatite scaffold connectivity making is good, moderate strength.
(3) hydroxyapatite scaffold making, owing to removing the cellular loose structure of class staying after microsphere, can effectively promote medicine, the absorption of albumen, thus prominently while making medicine carrying hydroxyapatite drug release to release littlely, release time is long.
(4) timbering material is hydroxyapatite, is the main inorganic composition of biological skeleton, has good biocompatibility with sclerous tissues, has good affinity and bone conductibility with sclerous tissues.
(5) preparation method technique is simple, and equipment is not had to excessive demand, and raw material is easy to get, with low cost, is easy to realize industrialization.
Accompanying drawing explanation
Fig. 1 is the tablets in vitro curve that carries VEGF porous hydroxyapatite support of embodiment 1,2 and 3 preparations.
The specific embodiment
Below in conjunction with embodiment, the invention will be further described, but the scope of protection of present invention is not limited in this.
Embodiment 1
(1) the PLGA microsphere of 25～50 μ m is poured in mould, in baking oven, in 70 ℃, placed 10min and make it to bond a little, obtain porous PLGA support;
(2) 2g porous PLGA support is soaked in to 0.08molL
-1200ml ammonium dibasic phosphate solution in, with the speed of 1 drop/sec, drip 0.36molL
-1100mL calcium nitrate aqueous solution, then use ammonia adjust pH to 10, reactant is in 75 ℃ of ageings after 5 days, with distilled water wash product 3 times, in 50 ℃ of oven dry, then within 6 hours, removes PLGA in 400 ℃ of calcinings, obtains the hydroxyapatite scaffold of porous UNICOM;
(3) hydroxyapatite scaffold of porous UNICOM is soaked in the VEGF solution of 50 μ g/ml, is placed in vacuum desiccator and keeps 60min, then lyophilization is 40 hours, obtains carrying the porous hydroxyapatite support of VEGF, in 4 ℃ of sealings, saves backup.
Carry the experiment of VEGF porous hydroxyapatite support tablets in vitro curve: 2mg is carried to VEGF porous hydroxyapatite support, and to add PBS buffer to cumulative volume be 10mL, after sealing, maintain the temperature at 37 ± 1 ℃, under 60rpm, be placed in Forma481 type shaking table (Forma company, the U.S.) jolting in, at set intervals, utilize the VEGF concentration in determined by ultraviolet spectrophotometry supernatant, according to the medication amount dropping into and the volume of supernatant, can calculate the now percentage ratio of drug release; Get after liquid toward adding fresh PBS buffer to cumulative volume in precipitation is 10mL at every turn, continues jolting; Discharging total time is 21 days, obtains drug release curve according to time and cumulative release percentage ratio.Result as shown in Figure 1, can find out, VEGF the first Tiantu is released and is about 20% left and right, and slow-release time is long; During by the 21st day, cumulative release amount is 87.21%.Overall had good sustained release effect.
Embodiment 2
(1) the PLGA microsphere of 150～200 μ m is poured in mould, in baking oven, in 65 ℃, placed 20min and make it to bond a little, obtain porous PLGA support;
(2) 3g porous PLGA support is soaked in to 0.11molL
-1150ml ammonium dibasic phosphate solution in, with the speed of 2 drops/sec, drip 0.24molL
-1150ml calcium nitrate solution, then use ammonia adjust pH to 9, reactant is in 65 ℃ of ageings after 6 days, with distilled water wash product 4 times, in 30 ℃ of oven dry, then within 4 hours, removes PLGA in 600 ℃ of calcinings, obtains the hydroxyapatite scaffold of porous UNICOM;
(3) hydroxyapatite scaffold of porous UNICOM is soaked in the VEGF solution of 120 μ g/ml, is placed in vacuum desiccator and keeps 90min, then lyophilization is 50 hours, obtains carrying the porous hydroxyapatite support of VEGF, in 4 ℃ of sealings, saves backup.
Carry the experiment of VEGF porous hydroxyapatite support tablets in vitro curve: 2mg is carried to VEGF porous hydroxyapatite support, and to add PBS buffer to cumulative volume be 10mL, after sealing, maintain the temperature at 37 ± 1 ℃, under 60rpm, be placed in Forma481 type shaking table (Forma company, the U.S.) jolting in, at set intervals, utilize the VEGF concentration in determined by ultraviolet spectrophotometry supernatant, according to the medication amount dropping into and the volume of supernatant, can calculate the now percentage ratio of drug release; Get after liquid toward adding fresh PBS buffer to cumulative volume in precipitation is 10mL at every turn, continues jolting; Discharging total time is 21 days, obtains drug release curve according to time and cumulative release percentage ratio.Result as shown in Figure 1, can find out, VEGF the first Tiantu is released and is about 20% left and right, and slow-release time is long; During by the 21st day, cumulative release amount is 95.82%.Overall had good sustained release effect.
Embodiment 3
(1) the PLGA microsphere of 100～150 μ m is poured in mould, in baking oven, in 50 ℃, placed 30min and make it to bond a little, obtain porous PLGA support;
(2) 4g porous PLGA support is soaked in to 0.16molL
-1100ml ammonium dibasic phosphate solution in, with the speed of 3 drops/sec, drip 0.18molL
-1200ml calcium nitrate solution, then use ammonia adjust pH to 12, reactant is in 90 ℃ of ageings after 4 days, with distilled water wash product 5 times, in 45 ℃ of oven dry, then within 3 hours, removes PLGA in 800 ℃ of calcinings, obtains the hydroxyapatite scaffold of porous UNICOM;
(3) hydroxyapatite scaffold of porous UNICOM is soaked in the VEGF solution of 150 μ g/ml, is placed in vacuum desiccator and keeps 30min, then lyophilization is 60 hours, obtains carrying the porous hydroxyapatite support of VEGF, in 4 ℃ of sealings, saves backup.
Carry the experiment of VEGF porous hydroxyapatite support tablets in vitro curve: 2mg is carried to VEGF porous hydroxyapatite support, and to add PBS buffer to cumulative volume be 10mL, after sealing, maintain the temperature at 37 ± 1 ℃, under 60rpm, be placed in Forma481 type shaking table (Forma company, the U.S.) jolting in, at set intervals, utilize the VEGF concentration in determined by ultraviolet spectrophotometry supernatant, according to the medication amount dropping into and the volume of supernatant, can calculate the now percentage ratio of drug release; Get after liquid toward adding fresh PBS buffer to cumulative volume in precipitation is 10mL at every turn, continues jolting; Discharging total time is 21 days, obtains drug release curve according to time and cumulative release percentage ratio.Result as shown in Figure 1, can find out, VEGF the first Tiantu is released and is about 20% left and right, and slow-release time is long; During by the 21st day, cumulative release amount is 91.34%.Overall had good sustained release effect.
Table 1 is the hole parameter of the porous hydroxyapatite support of embodiment 1,2,3 preparations, and as shown in Table 1, the porosity of porous hydroxyapatite support prepared by the present invention is high, almost connects completely, and mechanical strength is moderate.
The hole parameter of porous hydroxyapatite support prepared by table 1 embodiment
Claims (6)
1. carry a preparation method for VEGF porous hydroxyapatite support, it is characterized in that, comprise the following steps:
(1) the PLGA microsphere of 25 ~ 200 μ m is poured in mould, in baking oven, 50 ~ 70 ℃ of placement 10 ~ 30min obtain porous PLGA support;
(2) porous PLGA support is soaked in to 0.08 ~ 0.16molL
-1100 ~ 200mL ammonium dibasic phosphate aqueous solution in, with the speed of 1 ~ 3 drop/sec, drip 0.18 ~ 0.36molL
-1100 ~ 200mL calcium nitrate aqueous solution, then use ammonia adjust pH to 9 ~ 12, reactant after 4 ~ 6 days, is used distilled water wash product in 65 ~ 90 ℃ of ageings, in 30 ~ 50 ℃ of oven dry, then removes PLGA in 400 ~ 800 ℃ of calcinings, obtains the hydroxyapatite scaffold of porous UNICOM;
(3) hydroxyapatite scaffold of porous UNICOM is soaked in the VEGF solution of 50 ~ 150 μ g/mL, is placed in vacuum desiccator and keeps 30 ~ 90min, then lyophilization, obtains carrying the porous hydroxyapatite support of VEGF, in 4 ℃ of sealings, saves backup.
2. the preparation method of a kind of year according to claim 1 VEGF porous hydroxyapatite support, is characterized in that, described in step (2), the mass volume ratio of PLGA support and ammonium dibasic phosphate solution is (1 ~ 4): 100g/mL.
3. the preparation method of a kind of year according to claim 1 VEGF porous hydroxyapatite support, is characterized in that, in step (2), the calcium phosphorus atoms ratio of described calcium nitrate solution and ammonium dibasic phosphate solution is (1.66 ~ 1.68): 1.
4. the preparation method of a kind of year according to claim 1 VEGF porous hydroxyapatite support, is characterized in that, described in step (2), calcination time is 3 ~ 6h.
5. the preparation method of a kind of year according to claim 1 VEGF porous hydroxyapatite support, is characterized in that, described in step (2), with distilled water wash product number of times, is 3 ~ 5 times.
6. the preparation method of a kind of year according to claim 1 VEGF porous hydroxyapatite support, is characterized in that, in step (3), described sublimation drying is 40 ~ 60h.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410005889.2A CN103751838B (en) | 2014-01-06 | 2014-01-06 | The preparation method of a kind of year VEGF porous hydroxyapatite support |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410005889.2A CN103751838B (en) | 2014-01-06 | 2014-01-06 | The preparation method of a kind of year VEGF porous hydroxyapatite support |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103751838A true CN103751838A (en) | 2014-04-30 |
| CN103751838B CN103751838B (en) | 2015-09-02 |
Family
ID=50519258
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410005889.2A Active CN103751838B (en) | 2014-01-06 | 2014-01-06 | The preparation method of a kind of year VEGF porous hydroxyapatite support |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103751838B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105031718A (en) * | 2015-08-27 | 2015-11-11 | 华南理工大学 | Bone repair porous compound scaffold based on 3D (three-dimensional)-Bioplotter printing technology and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080095815A1 (en) * | 2004-10-22 | 2008-04-24 | The Board Of Trustees Of The University Of Illinois | Hollow and Porous Orthopaedic or Dental Implant that Delivers a Biological Agent |
| CN102701172A (en) * | 2012-06-21 | 2012-10-03 | 昆明理工大学 | Method for preparing hydroxyapatite nanocrystals or microcrystals by using plant as template |
| CN103101895A (en) * | 2013-03-11 | 2013-05-15 | 山东轻工业学院 | Method for preparing porous hydroxyapatite by using polystyrene as template |
| CN103120921A (en) * | 2012-12-20 | 2013-05-29 | 华南理工大学 | Phosphorite hollow microsphere and preparation method thereof |
-
2014
- 2014-01-06 CN CN201410005889.2A patent/CN103751838B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080095815A1 (en) * | 2004-10-22 | 2008-04-24 | The Board Of Trustees Of The University Of Illinois | Hollow and Porous Orthopaedic or Dental Implant that Delivers a Biological Agent |
| CN102701172A (en) * | 2012-06-21 | 2012-10-03 | 昆明理工大学 | Method for preparing hydroxyapatite nanocrystals or microcrystals by using plant as template |
| CN103120921A (en) * | 2012-12-20 | 2013-05-29 | 华南理工大学 | Phosphorite hollow microsphere and preparation method thereof |
| CN103101895A (en) * | 2013-03-11 | 2013-05-15 | 山东轻工业学院 | Method for preparing porous hydroxyapatite by using polystyrene as template |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105031718A (en) * | 2015-08-27 | 2015-11-11 | 华南理工大学 | Bone repair porous compound scaffold based on 3D (three-dimensional)-Bioplotter printing technology and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103751838B (en) | 2015-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sun et al. | 3D printed calcium phosphate scaffolds with controlled release of osteogenic drugs for bone regeneration | |
| WO2018072679A1 (en) | Biomimetic biomineralized artificial bone repair material and preparation method therefor and use thereof | |
| CN101461963B (en) | Multiplex composite bone tissue engineering bracket material capable of degrading gradiently and preparation method thereof | |
| Tang et al. | Enhancement and orchestration of osteogenesis and angiogenesis by a dual-modular design of growth factors delivery scaffolds and 26SCS decoration | |
| CN105031718B (en) | Bone repair porous composite scaffold based on 3D-Bioplotter printing technology and preparation method thereof | |
| CN101361715B (en) | Preparation method of drug-carrying hydroxylapatite microspheres and bone cement composite porous microspheres | |
| Peña et al. | An alternative technique to shape scaffolds with hierarchical porosity at physiological temperature | |
| CN103495210A (en) | Chitosan-hydroxylapatite in-situ loaded icariin composite microspheres | |
| CN105288740A (en) | Method for preparation of controlled pore size biphasic calcium phosphate composite ceramic scaffold | |
| CN101773685B (en) | Method for preparing high-elasticity support for promoting cartilage regeneration in situ | |
| CN104368040B (en) | The 3D of a kind of compound decalcified bone matrix prints porous metals support and preparation method thereof | |
| CN108939162A (en) | A kind of preparation method of mesoporous bioglass/sodium alginate-sodium alginate layering bone tissue engineering scaffold | |
| CN108339153A (en) | A kind of 3D printing porous tissue engineering scaffold composite material and preparation method | |
| CN103083723A (en) | Collagen/nano-crystalline cellulose skin regenerative material, preparation method and application thereof | |
| Raja et al. | Multifunctional calcium-deficient hydroxyl apatite–alginate core–shell-structured bone substitutes as cell and drug delivery vehicles for bone tissue regeneration | |
| CN102552985B (en) | Silk fibroin/calcium phosphate bone cement-based porous composite material and preparation method thereof | |
| CN101091805A (en) | Lumpish biologic bracket material with diplopore and preparation method | |
| CN104288831A (en) | Bioactive degradable hybrid microsphere and preparation method and application thereof | |
| CN103143058B (en) | Preparation of composite hydrogel tissue engineer cartilage repairing scaffold with biological activity | |
| CN103751838B (en) | The preparation method of a kind of year VEGF porous hydroxyapatite support | |
| Wang et al. | Injectable, high specific surface area cryogel microscaffolds integrated with osteoinductive bioceramic fibers for enhanced bone regeneration | |
| CN102626526A (en) | Novel active absorbable bone cement material | |
| CN112604033A (en) | Composite material for bones and preparation method and application thereof | |
| CN103751116B (en) | A kind of preparation method of carrying gentamycin sulfate porous hydroxyapatite/PLGA microsphere | |
| CN102580145B (en) | Method for preparing phosphomycin calcium/hexagonal mesoporous silicon/poly glycolide-co-lactide (PLGA) bone tissue stent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220211 Address after: 510098 room 3513, No. 372, Huanshi East Road, Yuexiu District, Guangzhou, Guangdong Patentee after: Guangzhou Zhikun Biotechnology Co.,Ltd. Address before: 510640 No. five, 381 mountain road, Guangzhou, Guangdong, Tianhe District Patentee before: SOUTH CHINA University OF TECHNOLOGY |